SCHEMBL917255

SCHEMBL917255

O=S(=O)(O)CCCN1CCCc2ccccc21

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.57
DRD4 P21917 1/20 0.57
DRD3 P35462 1/20 0.57
ALDH1A1 P00352 3/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
CHRM2 P08172 12/20 0.56
CHRM4 P08173 12/20 0.56
CHRM1 P11229 12/20 0.56
CHRM3 P20309 11/20 0.56
PARP2 Q9UGN5 1/20 0.50
GAA P10253 1/20 0.50
USP2 O75604 1/20 0.50
CDK4 P11802 1/20 0.50
ALOX15 P16050 1/20 0.50
CCND1 P24385 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2168308 0.91 ALDH1A1 (0.62) DRD2DRD4DRD3ALDH1A1MEN1
SCHEMBL7628788 0.87 ALDH1A1 (0.60) DRD2DRD4DRD3ALDH1A1MEN1
SCHEMBL2743840 0.82 CHRM2 (0.54) DRD2DRD4DRD3ALDH1A1MEN1
SCHEMBL1916246 0.82 CHRM2 (0.56) ALDH1A1MEN1KMT2ACHRM2CHRM4
SCHEMBL20148244 0.81 ALDH1A1 (0.70) DRD2DRD4DRD3ALDH1A1MEN1
SCHEMBL10411259 0.81 HDAC1 (0.49) DRD2DRD4DRD3ALDH1A1MEN1
SCHEMBL9816060 0.81 HDAC1 (0.47) DRD2DRD4DRD3ALDH1A1MEN1
SCHEMBL5253343 0.80 ALDH1A1 (0.60) ALDH1A1MEN1KMT2ACHRM2CHRM4
SCHEMBL2743854 0.80 ADRA1B (0.42) DRD2DRD4DRD3ALDH1A1MEN1
SCHEMBL7951597 0.79 ALDH1A1 (0.77) ALDH1A1MEN1KMT2ACHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4726304-B2 2011-07-20 JP claimed
EP-1227803-B1 COMPOUNDS FOR INHIBITING IAPP-ASSOCIATED AMYLOID DEPOSITS BELLUS HEALTH INTERNATIONAL LTD (CH) 2010-05-05 EP claimed
US-20050048000-A1 Amyloid targeting imaging agents and uses thereof NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2005-03-03 US claimed
US-6783731-B1 FOR DETERMINING ACETAMINOPHEN IN BIOLOGICAL FLUIDS COMPRISING ENZYMES AND OTHER REAGENTS WHICH REMAIN ACTIVE WHEN COMBINED AND COATED IN DRY FORMAT AND WHICH GIVE A CLEAR AND PRECISE SIGNAL ON OXIDATIVE COUPLING WITH A SUITABLE COUPLER ORTHO-CLINICAL DIAGNOSTICS, INC. 2004-08-31 US claimed
JP-2003517458-A 2003-05-27 JP claimed
EP-1303311-A2 AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF Neurochem, Inc. (CA) 2003-04-23 EP claimed
EP-1276483-A2 COMPOSITIONS AND METHODS FOR TREATING AMYLOIDOSIS USING SULPHONATE DERIVATIVES QUEEN'S UNIVERSITY AT KINGSTON (CA) 2003-01-22 EP claimed
US-20020115717-A1 Amyloid targeting imaging agents and uses thereof NEUROCHEM (INTERNATIONAL) LIMITED (GI) 2002-08-22 US claimed
EP-0750197-B1 Dry analytical element for acetaminophen assay JOHNSON & JOHNSON CLIN DIAG (US) 2002-04-24 EP claimed
WO-2002007781-A2 AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF NEUROCHEM INC. (CA) 2002-01-31 WO claimed
EP-0580070-B1 Dry analytical element for acetaminophen assay JOHNSON & JOHNSON CLIN DIAG (US) 2001-03-14 EP claimed
WO-2000064420-A2 COMPOSITIONS AND METHODS FOR TREATING AMYLOIDOSIS USING SULPHONATE DERIVATIVES QUEEN'S UNIVERSITY AT KINGSTON (CA) 2000-11-02 WO claimed
US-6015683-A SUPPORT WITH REAGENT LAYER COMPRISING ASCORBATE OXIDASE, TYROSINASE, OR LACCASE; AN ARYL ACYLAMIDASE; AND 1-(3-SULFOPROPYL)-1,2,3,4-TETRAHYDROQUINOLINE; FOR ACCURATE, RAPID QUANTITATIVE DETERMINATION IN AQUEOUS FLUIDS CLINICAL DIAGNOSTIC SYSTEMS, INC. (US) 2000-01-18 US claimed
EP-0750197-A2 Dry analytical element for acetaminophen assay JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) 1996-12-27 EP claimed
EP-0580070-A2 Dry analytical element for acetaminophen assay Johnson & Johnson Clinical Diagnostics, Inc. (US) 1994-01-26 EP claimed
US-20140329746-A1 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2014-11-06 US disclosed
US-20140329746-A1 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2014-11-06 US disclosed
US-4672029-A SENSITIVE AT LOW CONCENTRATIONS EASTMAN KODAK COMPANY (US) 1987-06-09 US disclosed
EP-0184437-A2 Color-forming couplers and their use in the analytical determination of hydrogen peroxide or other analytes EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1986-06-11 EP disclosed
EP-0168035-A2 Use of anilin derivatives as coupling agents in oxidative colour-forming reactions Roche Diagnostics GmbH (DE) 1986-01-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050048000-A1 Amyloid targeting imaging agents and uses thereof APP, APBA1, BACE1 DRD2 4032/4885DRD4 3652/4885DRD3 3595/4885
US-20020115717-A1 Amyloid targeting imaging agents and uses thereof APP, APBA1, BACE1 DRD2 4032/4885DRD4 3652/4885DRD3 3595/4885
US-20140329746-A1 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES APP, PSEN1, PSEN2 DRD2 4826/4885DRD4 4784/4885DRD3 4771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.